For SC implantation, we chose a classic administration schedule, namely weekly intraperitoneal administrations of 12.5mg/kg anti-PD-1 antibodies, initiated once tumor volumes were 150mm3 (Figure 1A). Here, PDCD1 is linked to neoplasm.